Alder Biopharmaceuticals Inc (ALDR) Expected to Announce Earnings of -$1.03 Per Share
Wall Street brokerages predict that Alder Biopharmaceuticals Inc (NASDAQ:ALDR) will post ($1.03) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Alder Biopharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.36) and the highest estimate coming in at ($0.88). Alder Biopharmaceuticals posted earnings of ($0.80) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 28.8%. The business is scheduled to issue its next earnings report on Monday, February 25th.
According to Zacks, analysts expect that Alder Biopharmaceuticals will report full-year earnings of ($4.59) per share for the current financial year, with EPS estimates ranging from ($5.04) to ($4.25). For the next year, analysts forecast that the firm will post earnings of ($3.45) per share, with EPS estimates ranging from ($5.45) to ($1.73). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that follow Alder Biopharmaceuticals.
Alder Biopharmaceuticals (NASDAQ:ALDR) last released its earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($1.13) by $0.22.
In other Alder Biopharmaceuticals news, insider John A. Latham sold 24,999 shares of Alder Biopharmaceuticals stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $17.99, for a total value of $449,732.01. Following the completion of the sale, the insider now directly owns 268,692 shares in the company, valued at $4,833,769.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey T. L. Smith sold 5,040 shares of the business’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $18.00, for a total transaction of $90,720.00. Following the completion of the sale, the director now owns 5,871 shares of the company’s stock, valued at $105,678. The disclosure for this sale can be found here. Insiders have sold 90,120 shares of company stock worth $1,407,922 over the last ninety days. 17.40% of the stock is currently owned by insiders.
Several institutional investors have recently modified their holdings of ALDR. SG Americas Securities LLC acquired a new stake in shares of Alder Biopharmaceuticals in the second quarter worth $107,000. Pacer Advisors Inc. acquired a new stake in shares of Alder Biopharmaceuticals in the third quarter worth $118,000. Tower Research Capital LLC TRC acquired a new stake in shares of Alder Biopharmaceuticals in the second quarter worth $128,000. Xact Kapitalforvaltning AB acquired a new stake in shares of Alder Biopharmaceuticals in the first quarter worth $142,000. Finally, LPL Financial LLC acquired a new stake in shares of Alder Biopharmaceuticals in the first quarter worth $156,000. Institutional investors and hedge funds own 98.86% of the company’s stock.
Alder Biopharmaceuticals stock opened at $12.72 on Friday. The company has a market capitalization of $869.80 million, a PE ratio of -2.57 and a beta of 2.70. The company has a current ratio of 15.34, a quick ratio of 15.34 and a debt-to-equity ratio of 0.97. Alder Biopharmaceuticals has a fifty-two week low of $10.05 and a fifty-two week high of $20.87.
Alder Biopharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland.
Featured Story: Understanding Analyst Recommendations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.